|
| | Clodronate disodium Basic information |
| | Clodronate disodium Chemical Properties |
| Melting point | >330°C | | storage temp. | room temp | | solubility | Freely soluble in water, practically insoluble in ethanol (96 per cent), slightly soluble in methanol. | | form | Solid | | color | White to Off-White | | InChIKey | HJKBJIYDJLVSAO-UHFFFAOYSA-L | | CAS DataBase Reference | 22560-50-5(CAS DataBase Reference) |
| WGK Germany | 3 | | RTECS | SZ7640700 | | HS Code | 29319090 | | Toxicity | mouse,LD50,intraperitoneal,780mg/kg (780mg/kg),British UK Patent Application. Vol. #2096889, |
| | Clodronate disodium Usage And Synthesis |
| Description | Clodronate disodium is a bone resorption inhibitor, useful as adjunct therapy in the treatment of osteolytic bone metastases and malignant hypercalcemia. | | Chemical Properties | White Solid | | Originator | Proctor & Gamble (USA) | | Uses | Clodronic Acid Disodium Salt Hydrate is a bisphosphonate antiresorptive agent; bone resorption inhibitor. | | Definition | ChEBI: The disodium salt of clodronic acid. It inhibits bone resorption and soft tissue calcification, and is used (generally as the tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteoly
ic lesions and bone pain associated with skeletal metastases. | | Brand name | Bonefos (Leiras Oy, Finland). | | Hazard | Moderately toxic by ingestion.
| | Biochem/physiol Actions | Analog of pyrophosphate ion that inhibits the osteoclastic activity leading to bone resorption and osteoporosis. The compound is used in cancer research, especially in skeletal metastases and breast carcinoma. When entrapped in liposomes, it is used for macrophage-selective depletion (macrophage "suicide" technique), especially in spleen and liver. Found also to inhibit collagenase and matrix metalloproteinase1. | | Clinical Use | Bisphosphonate:
Management of osteolytic lesions, hypercalcaemia and
bone pain associated with skeletal metastases in patients
with breast cancer or multiple myeloma | | Safety Profile | A poison by intravenous route. Moderately toxic by ingestion, intraperitoneal routes. When heated to decomposition it emits toxic vapors of PO, and Cl- | | Drug interactions | Potentially hazardous interactions with other drugs
Cytotoxics: concentration of estramustine increased. | | Metabolism | Clodronate is not metabolised.
Over 70% of an intravenous dose is excreted unchanged
in the urine within 24 hours, the remainder being
sequestered to bone tissue. The substance which is bound
to bone is excreted more slowly, and the renal clearance is
about 75% of the plasma clearance. |
| | Clodronate disodium Preparation Products And Raw materials |
|
